In Brief: Telios/Integra LifeSciences
Telios/Integra LifeSciences: Companies sign letter of intent Feb. 9 whereby Plainsboro, N.J.-based Integra, which is developing artificial skin technologies, proposes to acquire Telios through the issuance of Integra stock in conjunction with the confirmation of a Telios Chapter 11 reorganization plan. Integra will issue up to 4 mil. shares of common stock at $8.75 per share to various Telios creditors and shareholders. The number of shares issued "will be subject to downward adjustment on a dollar-for-dollar basis in the event that less than $13 mil. in cash and receivables remain at Telios at closing." The transaction must be completed on or before July 1 and "is subject to the negotiation and execution of definitive agreements, confirmation of a plan of reorganization of Telios and cash reserves and receivables of not less than $12 mil. at Telios"...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth